Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu(II)ATSM in ALS
NCT04082832Phase 3Unknown
- Sponsor
- Vivat Therapeutics
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CuATSM in amyotrophic lateral sclerosis (ALS), sponsored by Vivat Therapeutics. Status: unknown.
02
Drugs
CuATSM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04082832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082832.